OBJECTIVE: We examined management strategies, overall survival (OS), and progression-free survival (PFS) among patients with PMNSGCTs undergoing resection and multidisciplinary management at a high-volume institution. SUMMARY OF BACKGROUND DATA: Outcomes after resection of PMNSGCTs are not well-characterized, with limited data on factors associated with survival. METHODS: We reviewed patients with PMNSGCT who underwent resection between 1980 and 2019. Median follow-up was 3.4 years. Preoperative therapy (including use of bleomycin), surgical management, recurrence, and survival were examined. Factors associated with survival were analyzed using Cox regression. RESULTS: In total, 113 patients were included [median age, 28 years (range, 16-65)]. Preoperative serum tumor markers (STMs) normalized/decreased in 74% of patients. Pathology included necrosis only (25%), teratoma +/- necrosis (20%), viable nonteratomatous germ cell tumor +/- teratoma (41%), and secondary somatic-type malignancy +/- teratoma (20%). Bleomycin chemotherapy was not associated with pulmonary complications or 90-day mortality. Patients receiving second-line chemotherapy followed by resection had significantly worse OS and PFS than patients receiving first-line chemotherapy followed by resection. On multivariable analysis, R1/R2 resection (HR, 3.92; P < 0.001) and increasing postoperative STMs (HR, 4.98; P < 0.001) were associated with shorter PFS; necrosis on pathology (HR, 0.42, P = 0.043) was associated with longer PFS. CONCLUSIONS: In patients with PMNSGCT undergoing resection, completeness of resection, postoperative pathology, and postoperative STMs were associated with PFS. Induction bleomycin was not associated with pulmonary complications or mortality in patients undergoing resection. Patients undergoing second-line chemotherapy followed by resection have a poor prognosis, with long-term survival of 22%.
OBJECTIVE: We examined management strategies, overall survival (OS), and progression-free survival (PFS) among patients with PMNSGCTs undergoing resection and multidisciplinary management at a high-volume institution. SUMMARY OF BACKGROUND DATA: Outcomes after resection of PMNSGCTs are not well-characterized, with limited data on factors associated with survival. METHODS: We reviewed patients with PMNSGCT who underwent resection between 1980 and 2019. Median follow-up was 3.4 years. Preoperative therapy (including use of bleomycin), surgical management, recurrence, and survival were examined. Factors associated with survival were analyzed using Cox regression. RESULTS: In total, 113 patients were included [median age, 28 years (range, 16-65)]. Preoperative serum tumor markers (STMs) normalized/decreased in 74% of patients. Pathology included necrosis only (25%), teratoma +/- necrosis (20%), viable nonteratomatous germ cell tumor +/- teratoma (41%), and secondary somatic-type malignancy +/- teratoma (20%). Bleomycin chemotherapy was not associated with pulmonary complications or 90-day mortality. Patients receiving second-line chemotherapy followed by resection had significantly worse OS and PFS than patients receiving first-line chemotherapy followed by resection. On multivariable analysis, R1/R2 resection (HR, 3.92; P < 0.001) and increasing postoperative STMs (HR, 4.98; P < 0.001) were associated with shorter PFS; necrosis on pathology (HR, 0.42, P = 0.043) was associated with longer PFS. CONCLUSIONS: In patients with PMNSGCT undergoing resection, completeness of resection, postoperative pathology, and postoperative STMs were associated with PFS. Induction bleomycin was not associated with pulmonary complications or mortality in patients undergoing resection. Patients undergoing second-line chemotherapy followed by resection have a poor prognosis, with long-term survival of 22%.
Authors: Inderpal S Sarkaria; Manjit S Bains; Shelly Sood; Camelia S Sima; Victor E Reuter; Raja M Flores; Robert J Motzer; George J Bosl; Valerie W Rusch Journal: J Thorac Oncol Date: 2011-07 Impact factor: 15.609
Authors: Aditya Bagrodia; Byron H Lee; William Lee; Eugene K Cha; John P Sfakianos; Gopa Iyer; Eugene J Pietzak; Sizhi Paul Gao; Emily C Zabor; Irina Ostrovnaya; Samuel D Kaffenberger; Aijazuddin Syed; Maria E Arcila; Raju S Chaganti; Ritika Kundra; Jana Eng; Joseph Hreiki; Vladimir Vacic; Kanika Arora; Dayna M Oschwald; Michael F Berger; Dean F Bajorin; Manjit S Bains; Nikolaus Schultz; Victor E Reuter; Joel Sheinfeld; George J Bosl; Hikmat A Al-Ahmadie; David B Solit; Darren R Feldman Journal: J Clin Oncol Date: 2016-09-30 Impact factor: 44.544
Authors: Kenneth A Kesler; Karen M Rieger; Zane T Hammoud; Laura E Kruter; Susan M Perkins; Mark W Turrentine; Bryan P Schneider; Lawrence H Einhorn; John W Brown Journal: Ann Thorac Surg Date: 2008-02 Impact factor: 4.330
Authors: Ting Zhi Liu; Dong Sheng Zhang; Ying Liang; Ning Ning Zhou; Hong Fei Gao; Ke Jun Liu; Hai Ying Wu Journal: J Cancer Res Clin Oncol Date: 2011-08-18 Impact factor: 4.553
Authors: Robert J Hamilton; Christina Canil; Noa Shani Shrem; Kopika Kuhathaas; Maria Di Jiang; Peter Chung; Scott North; Piotr Czaykowski; Sebastien Hotte; Eric Winquist; Christian Kollmannsberger; Armen Aprikian; Denis Soulières; Scott Tyldesley; Alan I So; Nicholas Power; Ricardo A Rendon; Martin O'Malley; Lori Wood; Michael A S Jewett Journal: Can Urol Assoc J Date: 2022-06 Impact factor: 2.052
Authors: Arnon Lavi; Eric Winquist; Shiva M Nair; Joseph L Chin; Jonathan Izawa; Ricardo Fernandes; Scott Ernst; Nicholas E Power Journal: Curr Oncol Date: 2020-12-08 Impact factor: 3.677
Authors: Raul Caso; Gregory D Jones; Kay See Tan; George J Bosl; Samuel A Funt; Joel Sheinfeld; Victor E Reuter; David Amar; Gregory Fischer; Daniela Molena; Gaetano Rocco; Manjit S Bains; Darren R Feldman; David R Jones Journal: Ann Thorac Surg Date: 2020-08-31 Impact factor: 4.330
Authors: Camilo Vallejo-Yepes; Carlos Andrés Carvajal-Fierro; Ricardo Brugés-Maya; Julian Beltrán; Ricardo Buitrago; Rafael Beltrán-Jimenez; José Alexander Carreño-Dueñas Journal: Front Oncol Date: 2022-01-03 Impact factor: 6.244